| Topic | Issue # |
| Abacavir + tenofovir + 3TC failure | 393 |
| Abbott raises Norvir price five fold | 397 |
| Access for all, Thailand conference theme | 395 |
| ADAP organizing | 388 |
| ADAP Washington trip | 397 |
| Aegis | 388 |
| Africa Action | 390 |
| Africa trials -- no drugs | 391 |
| African-Americans and AIDS Conference | 388, 397 |
| AIDS Treatment News online publication | 397 |
| AIDS Treatment News | 396 |
| Antibiotic-resistant staph | 388 |
| Atazanavir (Reyataz) approved | 392 |
| Bahamas antiretroviral prices, Clinton | 389 |
| Biomedical research cuts | 392 |
| Bush AIDS initiative | 388, 391 |
| Buyers' club lists | 397 |
| Cholesterol management | 394 |
| Ciasullo, Eric, on returning to work | 395 |
| Clinical Care Options for Hepatitis | 391 |
| Clinical Care Options | 388 |
| Clinton Foundation lowers Caribbean price | 389 |
| Clinton Foundation, HAART 40 cents/day | 395 |
| Cohen, Dr. Cal, on Retroviruses conf., pt. 1 | 389 |
| Cohen, Dr. Cal, on Retroviruses conf., pt. 2 | 390 |
| Co-trimoxazole for staph | 388 |
| Counterfeit Procrit | 389 |
| Deep salvage | 390 |
| Drug development | 397 |
| Efavirenz vs. nevirapine | 389 |
| Emtriva (FTC) approved | 393 |
| Export problem, WTO | 394 |
| Federal policy problems | 392 |
| Fosamprenavir approved | 395 |
| FTC (Emtriva) approved | 393 |
| Fundraising, online | 392 |
| FUZEON (T-20) | 389 |
| Glaxo research grants | 391 |
| Global Fund to Fight AIDS, TB, and Malaria | 388 |
| Grassroots organizing | 388 |
| Heart disease guidelines | 394 |
| Highly experienced patients | 390 |
| HIV Insite | 388 |
| HIV nutrition info for doctors | 391 |
| HIV treatment guidelines, July | 393 |
| HIV treatment guidelines, November 2003 | 396 |
| HIVandHepatitis.com | 388 |
| Hoffmann-La Roche, T-20 | 389 |
| Huge price variations in generics | 391 |
| IAS conference reports on Web | 393 |
| International AIDS Society conf., Paris | 392 |
| Lexiva (908, Fosamprenavir) | 389 |
| Lexiva approved | 395 |
| Medicaid cuts planned | 390 |
| Medicaid organizing | 388 |
| Medscape | 388 |
| Microbicides | 391 |
| MRSA | 388 |
| NATAP | 388 |
| Nelson Mandela on HIV treatment access | 393 |
| Neuropathy treatment, new guidelines | 396 |
| Nevirapine reduced maternal transmission | 394 |
| Nevirapine toxicity | 389 |
| Nevirapine vs. efavirenz | 389 |
| Norvir price fivefold rise | 397 |
| Paris conference reports on Web | 393 |
| Pediatric HIV guidelines, November 2003 | 396 |
| Pharmaceutical company lobbying facts | 397 |
| Pharmacy benefits managers, profit | 391 |
| Philadelphia FIGHT | 391 |
| Planetwork conference | 392 |
| Pneumocystis still cause of death in U.S. | 391 |
| Prevention policy problems | 392 |
| Prices of drugs | 391 |
| Prison Health News | 390 |
| Prison skin infections | 388 |
| Retroviruses conference, Web coverage | 388 |
| Returning to work after disability | 395 |
| Reyataz approved | 392 |
| Safety net failure | 391 |
| SARS Web information | 390 |
| Save ADAP committee | 397 |
| Search for a Cure, clinical trials forum | 395 |
| Social network software, for fundraising | 392 |
| Social Security disability definition | 392 |
| Staph infection treatments | 388 |
| Starting antiretroviral therapy | 389 |
| Subscriptions to share | 396 |
| T-20 cost | 389 |
| TAC (Treatment Action Campaign) | 390 |
| Tenofovir + ddI + 3TC failure | 395 |
| Thailand conference 2004, deadlines | 395 |
| The Body Web site | 388 |
| Treatment Action Campaign | 390 |
| Treatment interruption | 390, 394 |
| Triglycerides management | 394 |
| Trizivir arm stopped in trial | 390 |
| UNAIDS report for 2003 | 396 |
| VaxGen's AIDSVAX trial | 389 |
| World AIDS: $4.7 billion -- WorldCom: $35 billion | 396 |
| World Trade Organization rules | 394 |
| WORLD, women and HIV | 391 |
| WTO rules limit access to poor countries | 394 |
E-Mail
Printable Single-Page
Glossary
Share
